ETON
Company Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79.95M | 39.01M | 31.64M | 21.25M | 21.83M | 39,000 | 959,000 | 0 | 0 |
| Net Income | (4.60M) | (3.82M) | (936,000) | (9.02M) | (1.96M) | (27.97M) | (18.32M) | (12.74M) | (7.16M) |
| EPS | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.02 | -1.99 | -0.41 |
| Free Cash Flow | 10.19M | 943,000 | 6.04M | 2.03M | (7.98M) | (22.40M) | (19.87M) | (8.38M) | (4.85M) |
| FCF / Share | 0.38 | 0.04 | 0.24 | 0.08 | -0.32 | -1.07 | -1.12 | -1.31 | -0.28 |
| Operating CF | 10.52M | 969,000 | 6.82M | 4.82M | (4.72M) | (22.35M) | (18.03M) | (8.14M) | (4.72M) |
| Total Assets | 92.11M | 76.12M | 31.74M | 25.03M | 27.46M | 26.32M | 17.07M | 28.33M | 13.44M |
| Total Debt | 31.02M | 29.92M | 5.40M | 6.52M | 6.70M | 7.14M | 4.56M | 0 | 0 |
| Cash & Equiv | 25.94M | 14.94M | 21.39M | 16.30M | 14.41M | 21.30M | 12.07M | 26.73M | 13.16M |
| Book Value | 26.15M | 24.43M | 15.48M | 13.08M | 17.63M | 15.66M | 10.55M | 26.30M | 12.13M |
| Return on Equity | -0.18 | -0.16 | -0.06 | -0.69 | -0.11 | -1.79 | -1.74 | -0.48 | -0.59 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.28M | 22.46M | 18.93M | 17.28M | 11.65M | 10.32M | 9.07M | 7.97M | 7.31M | 7.03M | 12.00M | 5.30M |
| Net Income | 1.48M | (1.93M) | (2.58M) | (1.57M) | (598,000) | 627,000 | (3.04M) | (811,000) | (2.26M) | (579,000) | 4.56M | (2.66M) |
| EPS | 0.06 | -0.07 | -0.10 | -0.06 | -0.02 | 0.02 | -0.12 | -0.03 | -0.09 | -0.02 | 0.18 | -0.11 |
| Free Cash Flow | (22.12M) | 11.74M | 7.96M | 2.09M | (777,000) | 2.95M | 1.25M | (4.36M) | (388,000) | 873,000 | 7.10M | (1.55M) |
| FCF / Share | -0.82 | 0.44 | 0.30 | 0.08 | -0.03 | 0.11 | 0.05 | -0.17 | -0.02 | 0.03 | 0.28 | -0.06 |
| Operating CF | (22.07M) | 12.03M | 7.96M | 2.09M | (765,000) | 2.95M | 1.25M | (2.47M) | 387,000 | 873,000 | 7.10M | (1.55M) |
| Total Assets | 92.11M | 104.51M | 101.68M | 84.03M | 76.12M | 35.84M | 31.82M | 30.79M | 31.74M | 31.53M | 30.93M | 23.93M |
| Total Debt | 9.25M | 3.26M | 30.67M | 30.08M | 29.92M | 4.33M | 4.88M | 5.11M | 5.46M | 5.78M | 6.16M | 6.53M |
| Cash & Equiv | 25.94M | 37.12M | 25.38M | 17.42M | 14.94M | 20.26M | 17.69M | 16.66M | 21.39M | 22.07M | 21.57M | 14.71M |
| Book Value | 26.15M | 23.13M | 23.96M | 24.45M | 24.43M | 15.98M | 13.46M | 15.49M | 15.48M | 16.89M | 16.73M | 11.24M |
| Return on Equity | 0.06 | -0.08 | -0.11 | -0.06 | -0.02 | 0.04 | -0.23 | -0.05 | -0.15 | -0.03 | 0.27 | -0.24 |